Renal cell carcinoma (RCC) is a kind of malignant tumor with high recurrence, and it is urgent to find molecular markers for diagnosis and prognosis of RCC. Our study investigated the expression and function of integrin alpha M beta 2 in RCC cells, aiming to understand the role of integrin alpha M beta 2 in RCC and develop new therapeutic target for RCC. Overexpression and knockdown of lymphoid enhancer-binding factor 1 (LEF1) were performed using vector containing full-length cDNA and via siRNA technology, respectively. The expressions of mRNA and protein were detected by RT-PCR and Western blot, respectively. Proliferation of RCC cell was analyzed using WST-1 assay, and metastasis of RCC cell was evaluated using the transwell system. Our results demonstrated that LEF1 and integrin alpha M beta 2 were up-regulated in RCC cells via TGF-beta 1-dependent mechanism, and LEF1 together with beta-catenin directly increased integrin alpha M beta 2 level. On the other hand, TGF-beta 1-induced proliferation, migration and invasion were suppressed by function-blocking antibody against integrin alpha M beta 2 in RCC cells. In addition, integrin alpha M beta 2 is crucial for LEF1 mediated cell invasion by regulating MMP-2, MMP-9 and calpain-2 secretion in RCC cells. LEF1/integrin alpha M beta 2 expression was regulated by TGF-beta 1, and LEF1/integrin alpha M beta 2 was involved in TGF-beta 1's improvement effects on the proliferation and metastasis of RCC. Blocking integrin alpha M beta 2 activity could be a therapeutic option for patients with advanced RCC.